NAP Peptide (Davunetide): The Neuroprotective Peptide Story
Neurodegenerative Disease Peptides
313 patients
The largest clinical trial of davunetide enrolled 313 people with progressive supranuclear palsy across 48 centers in six countries, making it one of the most thoroughly tested neuroprotective peptides in history.
Boxer et al., Lancet Neurology, 2014
Boxer et al., Lancet Neurology, 2014
View as imageDavunetide is an eight-amino-acid peptide (sequence: NAPVSIPQ) that protects neurons by stabilizing microtubules, the structural scaffolding inside every nerve cell. Derived from a larger protein called activity-dependent neuroprotective protein (ADNP), davunetide reached Phase 2/3 clinical trials for progressive supranuclear palsy (PSP), completed Phase 2 trials for amnestic mild cognitive impairment and schizophrenia, and is now being investigated for ADNP syndrome, a rare genetic neurodevelopmental disorder. For a broader look at how toxic peptide fragments drive neurodegeneration, see our pillar article on amyloid-beta and Alzheimer's disease. The davunetide story is one of the most complete case studies in neuroprotective peptide development: a molecule with strong preclinical data, genuine clinical testing, a pivotal trial failure, and a surprising reanalysis that reopened the scientific question.
Key Takeaways
- Davunetide (NAP/NAPVSIPQ) stabilizes microtubules and reduces tau hyperphosphorylation in multiple animal models of neurodegeneration (Gozes, Current Pharmaceutical Design, 2011)
- A 313-patient Phase 2/3 trial in progressive supranuclear palsy showed no overall benefit on primary endpoints over 52 weeks (Boxer et al., Lancet Neurology, 2014)
- A 2023 sex-stratified reanalysis found davunetide significantly slowed disease progression in women with PSP, with protection on the SEADL scale at 39 weeks (P = 0.008) (Gozes et al., Translational Psychiatry, 2023)
- In schizophrenia, 12 weeks of intranasal davunetide improved functional capacity (UPSA) with an effect size of 0.74 at the 5 mg dose (Javitt et al., Schizophrenia Research, 2012)
- In ALS mice, acute NAP treatment normalized axonal transport rates and chronic treatment significantly prolonged lifespan (Jouroukhin et al., Neurobiology of Disease, 2013)
- Davunetide has FDA orphan drug and rare pediatric disease designation for ADNP syndrome, a condition caused by mutations in the gene that produces NAP's parent protein
Where NAP Comes From: ADNP and Microtubule Biology
NAP is not a synthetic design. It is an eight-residue fragment of activity-dependent neuroprotective protein (ADNP), a protein that regulates more than 400 genes during embryonic brain development.[1] ADNP interacts with chromatin remodeling complexes (SWI/SNF) and is essential for neural tube closure. Complete ADNP knockout is lethal in mice. Even a 50% reduction (haploinsufficiency) produces cognitive deficits and tau pathology, the abnormal accumulation of hyperphosphorylated tau protein that characterizes Alzheimer's disease and other tauopathies.
The critical motif in NAP's sequence is SIP (serine-isoleucine-proline), which functions as an SH3 domain-ligand association site. This motif enables direct interaction with microtubule end-binding proteins, facilitating microtubule dynamics and tau-microtubule interactions.[1] In simpler terms: NAP helps hold the internal skeleton of nerve cells together. When tau detaches from microtubules (as happens in Alzheimer's, PSP, and other tauopathies), the microtubules destabilize and the neuron's transport system breaks down. NAP counteracts this process.
Gozes (2016) described the broader rationale: the cytoskeleton is a drug target for neuroprotection, and ADNP mutations (as seen in the Helsmoortel-Van der Aa syndrome, a form of autism) demonstrate what happens when this system fails.[2] NAP replacement therapy partially rescued the deficits in ADNP-haploinsufficient mice, establishing the peptide as a functional replacement for a missing endogenous protein rather than a purely pharmacological intervention.
Preclinical Evidence: What NAP Does in Animal Models
Microtubule Protection and Tau Pathology
NAP protects microtubules from multiple types of damage. In cell culture, it prevented microtubule disruption caused by zinc toxicity, the destabilizing agent nocodazole, and oxidative stress. In animal models, it reduced tau hyperphosphorylation in both ADNP-deficient mice and the triple transgenic Alzheimer's disease mouse model.[1]
The protection extends beyond simple structural reinforcement. NAP has been shown to shield microtubules from the severing protein katanin, which normally chops microtubules apart. When tau levels are reduced (mimicking the detachment that occurs in tauopathies), microtubules become hypersensitive to katanin. NAP restores their resistance.[1]
Axonal Transport Rescue in ALS Mice
Jouroukhin et al. (2013) provided one of the most detailed demonstrations of NAP's mechanism in a disease model. Using SOD1-G93A mice (a model for amyotrophic lateral sclerosis), they measured axonal transport rates with manganese-enhanced MRI and found significant reductions in the ALS mice compared to healthy controls.[3]
A single dose of NAP normalized axonal transport rates. Chronic daily treatment reduced tau hyperphosphorylation in the brain, protected spinal cord motor neurons from ALS-like pathology, and delayed degeneration of cranial motor nuclei (trigeminal, facial, and hypoglossal). The treated mice showed significant protection of the ventral tegmental area (VTA), a dopaminergic brain region, and VTA protection correlated with longevity. Overall, chronic NAP treatment significantly prolonged lifespan in these ALS mice.[3]
NAP also reversed axonal transport disruption caused by colchicine in healthy mice, confirming that the mechanism operates through microtubule stabilization rather than being specific to the ALS mutation.
Anti-Apoptotic Pathways
Beyond microtubule effects, NAP activates survival signaling. In cortical plate neurons, it reduced apoptosis through the PI3K/Akt pathway. In white matter, it activated both PI3K/Akt and MAPK/MEK1 kinase pathways.[1] These parallel mechanisms suggest NAP's neuroprotection is not limited to structural support but includes active signaling to prevent programmed cell death.
Diabetes-Associated Neurodegeneration
Idan-Feldman et al. (2011) tested davunetide in a diabetic rat model, demonstrating that it prevented central nervous system complications associated with diabetes, including cognitive deficits and neuronal damage.[4] This finding extended the potential applications of davunetide beyond classical neurodegenerative diseases to metabolic conditions with secondary neurological effects.
Clinical Trials: Four Studies in Humans
Amnestic Mild Cognitive Impairment (Phase 2)
The first human efficacy trial tested intranasal davunetide (AL-108) in 144 people with amnestic mild cognitive impairment (aMCI), a condition frequently preceding Alzheimer's disease. Participants received either 5 mg once daily, 15 mg twice daily, or placebo for 12 weeks. The treatment improved memory scores relative to placebo.[5] This was a small, short trial, but it established that intranasal davunetide reached the brain in sufficient concentrations to produce measurable cognitive effects, and it had no significant safety concerns.
Schizophrenia (Phase 2)
Javitt et al. (2012) conducted a 12-week multicenter, double-blind trial in 63 people with schizophrenia. Participants continued their current antipsychotic medications and received intranasal davunetide at 5 mg/day, 30 mg/day, or placebo.[6]
The primary cognitive outcome (MATRICS Consensus Cognitive Battery) did not reach statistical significance, with effect sizes of 0.34 and 0.21 for the 5 mg and 30 mg doses respectively. The functional capacity measure (UCSD Performance-based Skills Assessment, UPSA) did show a significant treatment effect (p = 0.048), with effect sizes of 0.74 for the 5 mg dose and 0.48 for the 30 mg dose. No significant adverse events were observed. The authors calculated that 45-50 subjects per group would be needed to achieve significant effects on both cognitive and functional measures, indicating the trial was underpowered for its primary endpoint.
Progressive Supranuclear Palsy: The Pivotal Trial (Phase 2/3)
The largest davunetide trial enrolled 313 participants with PSP across 48 centers in Australia, Canada, France, Germany, the UK, and the USA. This was a 52-week, double-blind, placebo-controlled study testing 30 mg intranasal davunetide twice daily.[7]
PSP was chosen because it is a "pure tauopathy," a neurodegenerative disease driven primarily by tau pathology without the amyloid-beta plaques that complicate Alzheimer's. If davunetide's microtubule-stabilizing, tau-protecting mechanism was going to work anywhere, PSP was the cleanest test.
The trial failed on both primary endpoints. The PSP Rating Scale (PSPRS) showed identical median changes from baseline in both groups (11.8 points, p = 0.41). The Schwab and England Activities of Daily Living (SEADL) scale also showed no difference (p = 0.92). Secondary and exploratory endpoints were also negative. The treatment was generally safe, though nasal adverse events were more common with davunetide: epistaxis (12% vs 8%), rhinorrhea (10% vs 5%), and nasal discomfort (10% vs <1%).[7]
This result effectively halted davunetide's clinical development for PSP and dampened enthusiasm for the peptide as a therapeutic for neurodegenerative tauopathies.
The 2023 Reanalysis: Sex Differences Change the Story
Gozes et al. (2023) reanalyzed the PSP trial data with sex stratification and found something the original analysis missed entirely.[8]
Women with PSP deteriorated significantly faster than men on the primary endpoints, with divergence visible by week 13 of the trial (P = 0.01). This faster female decline was consistent across most clinical endpoints by week 52.
In the placebo group, female patients showed dramatic correlations between baseline brain ventricular volume and 52-week volume increases (r = 0.74, P = 2.36 x 10^-9), a pattern not seen in men. In davunetide-treated women, this correlation disappeared, matching the male pattern. The treatment appeared to specifically counteract the accelerated female disease progression.
On the SEADL scale, davunetide-treated women showed significant protection compared to placebo-treated women as early as week 39 (P = 0.008). By week 52, treated women also showed protection in bulbar and limb motor domains on the PSPRS, including speaking, swallowing, and fine motor skills (P = 0.01). The exploratory Geriatric Depression Scale corroborated the finding: the placebo-treated women's depression scores correlated with functional decline, while davunetide-treated women were protected.[8]
This reanalysis does not prove davunetide works. It was not pre-specified, and post-hoc subgroup analyses carry a high risk of false positives. The finding does, however, raise a specific and testable hypothesis: that davunetide may be effective in female PSP patients but that the overall trial failed because the slower-progressing male patients diluted the treatment signal. Separately, the Huntington's disease peptide field faces similar challenges with disease heterogeneity obscuring treatment effects.
Safety Profile Across Trials
Morimoto et al. (2013) published a comprehensive review of davunetide safety and efficacy data across all clinical programs.[9] The intranasal formulation was consistently well tolerated. The most common adverse events were local nasal symptoms (discomfort, rhinorrhea, epistaxis), which were dose-related but generally mild. No systemic safety signals emerged across the clinical programs. No significant effects on vital signs, laboratory values, or electrocardiograms were observed.
The safety profile is relevant because it distinguishes davunetide from other neuroprotective strategies that carried serious risks. Small molecule microtubule stabilizers (like the taxane derivatives tested in neurodegenerative disease) have significant toxicity. Davunetide's peptide nature and intranasal delivery route produced a cleaner safety profile, even in year-long dosing.
ADNP Syndrome: A New Direction
The most active current direction for davunetide is ADNP syndrome (also called Helsmoortel-Van der Aa syndrome), a rare neurodevelopmental disorder caused by mutations in the ADNP gene. Children with ADNP mutations have intellectual disability, motor delays, and features overlapping with autism spectrum disorder. Because davunetide is a functional fragment of the protein these children are missing, it represents a direct replacement therapy rather than a pharmacological intervention targeting a downstream pathway.
Davunetide received FDA orphan drug and rare pediatric disease designation for ADNP syndrome. The European Medicines Agency (EMA) also granted orphan drug status. A Phase 3 trial began enrollment in late 2024, testing davunetide in approximately 97 children with confirmed ADNP mutations. The cerebrolysin neuroprotection research represents another peptide-based approach to neurodevelopmental and neurodegenerative conditions, though with a fundamentally different mechanism (neurotrophic factor mixtures rather than microtubule stabilization). The emerging field of peptide-based neuroplasticity modulation provides additional context for how peptides interact with neural repair mechanisms.
Why the PSP Trial Failed (And Whether It Really Did)
The PSP trial failure deserves closer examination because it illustrates broader challenges in neuroprotective drug development.
First, PSP may not have been the ideal test case despite being a pure tauopathy. PSP involves tau pathology in brainstem and basal ganglia structures that are already severely damaged at diagnosis. By the time clinical symptoms appear, substantial neuronal loss has occurred. A microtubule stabilizer may preserve remaining neurons but cannot replace lost ones. The same challenge confronts Alzheimer's peptide approaches and peptide vaccines targeting amyloid, where treatment often begins after irreversible damage has accumulated.
Second, the dose may have been suboptimal. The 30 mg twice daily intranasal dose was chosen based on earlier trial data, but there was no Phase 2 dose-finding study specifically in PSP. The schizophrenia trial actually showed larger effect sizes at the lower 5 mg dose than at 30 mg, suggesting a non-linear dose-response that was never fully characterized.
Third, the sex-dependent reanalysis suggests the trial may have been analyzing a mixed population with fundamentally different disease biology. If women with PSP have a more aggressive tau-driven disease course (as the baseline ventricular data suggest), and davunetide specifically counteracts that aggressive course, pooling the data with slower-progressing men would wash out the signal. This is not a general excuse for failed trials, but the specificity of the findings (consistent across multiple clinical and imaging endpoints, with a plausible biological mechanism) makes it worth investigating prospectively.
The Parkinson's peptide research field faces analogous challenges: protein aggregation diseases are biologically heterogeneous, and treatments that work in subpopulations can appear ineffective in undifferentiated trial designs.
Intranasal Delivery: A Practical Advantage
Davunetide's intranasal formulation is a practical advantage that often gets overlooked. Most neuroprotective peptides face the blood-brain barrier as their primary delivery obstacle. Intranasal peptide delivery bypasses this barrier through direct nose-to-brain transport along olfactory and trigeminal nerve pathways.
The clinical trial data confirmed that intranasally delivered davunetide produces measurable CNS effects (cognitive improvements in aMCI, functional improvements in schizophrenia, imaging changes in PSP), validating that the peptide reaches the brain at pharmacologically active concentrations. This is a meaningful data point for the broader field of intranasal peptide therapeutics.
What Remains Unknown
The biggest gap in the davunetide evidence base is a prospective, sex-stratified trial in PSP. The 2023 reanalysis generated a compelling hypothesis, but post-hoc analyses do not constitute proof. A trial specifically designed to test davunetide in women with PSP, with adequate power and pre-specified endpoints, is the next logical step. Whether this trial happens depends on funding and commercial interest in a rare disease indication.
The relationship between davunetide's preclinical efficacy (where it is consistently impressive) and its clinical performance (mixed at best in pooled analyses) remains partially unexplained. Animal models of neurodegeneration do not perfectly replicate human disease biology, disease duration, or the timing of treatment initiation.
The ADNP syndrome program represents the most straightforward clinical path. If davunetide helps children missing functional ADNP protein, it validates the entire biological rationale: that the NAP fragment of ADNP is the active neuroprotective component and that exogenous delivery can replace endogenous function. Results from this program will have implications beyond ADNP syndrome itself.
The Bottom Line
Davunetide (NAP) is an eight-amino-acid peptide derived from ADNP that stabilizes microtubules, reduces tau pathology, and activates neuronal survival pathways. It completed Phase 2 trials showing cognitive and functional benefits in aMCI and schizophrenia, and a 313-patient Phase 2/3 trial in PSP that failed on primary endpoints but showed significant efficacy in women upon sex-stratified reanalysis. Animal data consistently demonstrate neuroprotection, including lifespan extension in ALS mice. Current development focuses on ADNP syndrome, where davunetide has orphan drug designation and is in Phase 3 testing. The davunetide story illustrates both the promise and complexity of translating neuroprotective peptides from lab to clinic.